Fintel reports that on November 29, 2024, RBC Capital downgraded their outlook for Applied Therapeutics (NasdaqGM:APLT) from ...

Fintel reports that on November 26, 2024, RBC Capital initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) on November 25 and set a price ...

RBC Capital analyst Gregory Renza maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report) on November 25 and set a price ...

Strategists see falling inflation, resilient economic growth, and rising earnings driving further returns for the S&P 500 in ...

Power needs for artificial intelligence and cloud computing are expanding so rapidly that some data center campuses may use ...

Applied Therapeutics stock (APLT) was down 75% early Friday on news the FDA had declined to approve its drug govorestat, ...

As an investment banking associate at RBC Capital Markets, MBA graduate Emmanuel Fadahunsi is helping his clients drive ...

H&M is expected to continue expanding its presence, including a planned launch in Brazil next year. However, analysts remain ...

Investing.com -- RBC Capital Markets downgraded Applied Therapeutics Inc (NASDAQ: APLT) stock to "sector perform" from "outperform” citing increased risks after the U.S. Food and Drug Administration ...

On Monday, equity strategy teams at Barclays and RBC Capital Markets both issued a year-end target price of 6,600 for the S&P 500 (^GSPC) in 2025. The targets suggest a roughly 10.5% gain in the ...

Tariffs have taken the spotlight as a policy issue as S&P 500 companies have discussed earnings with analysts since the U.S.